Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 24.394
SA - Sud America 4.094
EU - Europa 3.988
NA - Nord America 3.798
AF - Africa 338
OC - Oceania 65
Continente sconosciuto - Info sul continente non disponibili 6
Totale 36.683
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 11.823
SG - Singapore 4.530
CN - Cina 3.795
BR - Brasile 3.064
US - Stati Uniti d'America 2.957
HK - Hong Kong 1.723
IT - Italia 784
RU - Federazione Russa 758
KR - Corea 651
MX - Messico 579
TR - Turchia 431
DE - Germania 419
ES - Italia 410
AR - Argentina 368
ID - Indonesia 278
GB - Regno Unito 256
IN - India 245
JP - Giappone 242
FR - Francia 193
CO - Colombia 181
CA - Canada 174
EC - Ecuador 147
AT - Austria 142
BD - Bangladesh 130
NL - Olanda 117
CL - Cile 106
PL - Polonia 106
FI - Finlandia 104
ZA - Sudafrica 93
EG - Egitto 83
SA - Arabia Saudita 81
SE - Svezia 80
PK - Pakistan 75
GR - Grecia 72
PT - Portogallo 66
VE - Venezuela 64
UA - Ucraina 62
IQ - Iraq 61
PY - Paraguay 60
CH - Svizzera 58
PE - Perù 57
AU - Australia 52
CZ - Repubblica Ceca 51
IL - Israele 45
MA - Marocco 44
TW - Taiwan 42
HU - Ungheria 39
RO - Romania 35
DZ - Algeria 34
NO - Norvegia 34
HR - Croazia 31
BE - Belgio 28
MD - Moldavia 28
PH - Filippine 26
TN - Tunisia 26
UZ - Uzbekistan 25
AE - Emirati Arabi Uniti 24
UY - Uruguay 24
BO - Bolivia 23
KZ - Kazakistan 21
CR - Costa Rica 20
KE - Kenya 20
SK - Slovacchia (Repubblica Slovacca) 20
DO - Repubblica Dominicana 19
TH - Thailandia 19
GT - Guatemala 18
IE - Irlanda 18
NP - Nepal 17
DK - Danimarca 15
AZ - Azerbaigian 14
NZ - Nuova Zelanda 13
LB - Libano 12
MY - Malesia 11
OM - Oman 11
AL - Albania 10
SI - Slovenia 9
SN - Senegal 9
LK - Sri Lanka 8
LT - Lituania 8
RS - Serbia 8
BY - Bielorussia 7
GE - Georgia 7
HN - Honduras 7
SY - Repubblica araba siriana 7
IR - Iran 6
JO - Giordania 6
XK - ???statistics.table.value.countryCode.XK??? 6
BG - Bulgaria 5
BH - Bahrain 5
BW - Botswana 5
EE - Estonia 5
ET - Etiopia 5
LV - Lettonia 5
CI - Costa d'Avorio 4
NG - Nigeria 4
NI - Nicaragua 4
PA - Panama 4
TT - Trinidad e Tobago 4
BN - Brunei Darussalam 3
JM - Giamaica 3
Totale 36.638
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 3.810
Hanoi 3.010
Singapore 2.051
Hong Kong 1.682
Hefei 1.644
Seoul 614
Ashburn 317
Haiphong 316
Da Nang 310
São Paulo 304
Ha Long 290
Los Angeles 263
Quận Bình Thạnh 245
Buffalo 234
Biên Hòa 231
Dallas 225
Hải Dương 200
Ninh Bình 193
Thái Nguyên 185
Vũng Tàu 174
Milan 169
Can Tho 162
Moscow 153
Beijing 139
Bắc Ninh 139
Istanbul 139
The Dalles 136
Rio de Janeiro 126
Bắc Giang 118
Jakarta 113
Quận Một 113
Quận Phú Nhuận 106
Chicago 105
Phủ Lý 102
Madrid 100
Rome 97
Quận Sáu 88
Ankara 87
Mexico City 85
Shanghai 84
Vinh 77
Frankfurt am Main 75
Guangzhou 74
Thái Bình 74
Lấp Vò 72
New York 72
Quận Tân Phú 69
Tokyo 68
Uyen Hung 68
Bogotá 67
Lang Son 67
Curitiba 65
Vienna 65
Điện Bàn 64
Buenos Aires 62
Brasília 61
Vĩnh Tường 59
Quito 58
Quận Năm 58
Guadalajara 55
Quảng Ninh 55
Thu Dau Mot 55
Barcelona 54
Belo Horizonte 54
Nuremberg 54
Paris 50
Quận Bảy 50
Santiago 49
Thành Phố Bà Rịa 49
Bình Dương 46
Cologne 46
Hangzhou 46
Bến Tre 45
Goiânia 45
Lappeenranta 45
Huế 44
Hòa Bình 44
Karachi 44
Lima 44
Thanh Hóa 43
London 42
Manchester 42
Porto Alegre 42
Riyadh 42
Tam Bình 42
Bạc Liêu 40
Fortaleza 39
Nam Định 39
Quảng Ngãi 39
Salvador 39
Xi'an 39
Guayaquil 37
Medellín 37
Quận Mười 37
Ribeirão Preto 37
Athens 35
Bình An 35
Cairo 35
Boston 34
Helsinki 34
Totale 21.717
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 3.020
Classification criteria for autoinflammatory recurrent fevers 1.501
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 1.078
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 698
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 502
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus 464
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 396
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 381
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 376
Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides 376
Macrophage Activation Syndrome in Juvenile Systemic Lupus Erythematosus A Multinational Multicenter Study of Thirty-Eight Patients 360
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 357
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 355
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 349
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 348
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 340
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 339
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs 333
Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? 331
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation 314
Localized scleroderma in childhood is not just a skin disease 311
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis 301
Criteria to define response to therapy in paediatric rheumatic diseases 295
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 283
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 277
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 240
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 231
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 217
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 215
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1) 211
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 211
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 208
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 200
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 192
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? 192
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis 187
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 187
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis 184
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 181
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis 179
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 179
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicenter PRINTO study 175
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 173
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial 170
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis 168
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 163
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 161
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus 155
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 153
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases 148
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 144
Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) 141
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 140
Adalimumab in Juvenile Rheumatoid Arthritis Reply 137
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 134
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 134
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis 133
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 132
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 131
The Paediatric Rheumatology International Trials Organisation Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis 127
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 126
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 124
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 122
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis 119
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 117
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 117
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 116
A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate 116
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 112
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 106
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey 106
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis 106
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 105
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study 105
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate 104
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 102
Porpora di Schönlein-Henoch in paziente con pregressa glomerulonefrite di Berger (Schönlein-Henoch purpura in patients with previous Berger's glomerulonephritis) 101
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 100
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study 98
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 97
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 94
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 88
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 87
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 87
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project 87
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 87
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 87
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 86
The Finnish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 83
Emerging therapies for juvenile arthritis: agents in early clinical trials 82
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 82
Correction: A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry [Pediatr Rheumatol., 15, (2017) (84)] DOI: 10.1186/s12969-017-0213-x 82
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 81
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 80
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 76
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review 76
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 75
Development and External Validation of a Model Predicting New-Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis 75
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 74
Totale 23.618
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.113
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.113
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202510.043 0 0 0 0 605 129 1.200 822 1.717 1.474 1.228 2.868
2025/202628.289 10.069 7.688 3.113 4.583 1.858 978 0 0 0 0 0 0
Totale 38.332